{"id":1580,"date":"2022-08-30T13:30:43","date_gmt":"2022-08-30T11:30:43","guid":{"rendered":"https:\/\/dextechmedical.com\/?p=1580"},"modified":"2022-08-30T12:46:17","modified_gmt":"2022-08-30T10:46:17","slug":"year-end-report-july-1-2021-june-30-2022","status":"publish","type":"post","link":"https:\/\/dextechmedical.com\/en\/year-end-report-july-1-2021-june-30-2022\/","title":{"rendered":"Year-end report July 1, 2021 &#8211; June 30, 2022"},"content":{"rendered":"<div class=\"page\" title=\"Page 1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Summary of the fourth quarter (2022-04-01 \u2013 2022-06-30)<\/strong><\/p>\n<ul>\n<li>Net sales amounted to MSEK 0,0 (0,0)<\/li>\n<li>Operating profit\/loss amounted to MSEK -2,1 (-1,5)<\/li>\n<li>Earnings per share* SEK -0.11 (-0.10)<\/li>\n<\/ul>\n<p>* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 14,920,478. Amounts in brackets refer to the corresponding period last year.<\/p>\n<p><strong>Summary of the financial year (2021-07-01 \u2013 2022-06-30)<\/strong><\/p>\n<ul>\n<li>Net sales amounted to MSEK 0,0 (0,0)<\/li>\n<li>Operating profit\/loss amounted to MSEK -5,3 (-6,1)<\/li>\n<li>Earnings per share* SEK -0.31 (-0.41)<\/li>\n<li>Cash and cash equivalents at the end of the period amounted to MSEK 35,5 (3,5)<\/li>\n<\/ul>\n<p>* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 16,790,364. For the comparison period, the average number of shares was 14,920,478. Amounts in brackets refer to the corresponding period last year.<\/p>\n<p><strong>CEO&#8217;s comment<\/strong><\/p>\n<p>The clinical myeloma study with the Company&#8217;s drug candidate OsteoDex, which was financed via a rights issue in December 2021 that brought the company SEK 37 million after issue costs, continues according to plan. The study application to the Swedish Medicines Agency has now been approved and permission was announced on August 10, 2022. The study will include 20 patients and will be conducted at 5 hospital centers in Sweden and Norway. The study is estimated to start during quarter 1 2023 at the latest and is estimated to be completed during quarter 3 2024.<\/p>\n<p>Our previous preclinical studies regarding OsteoDex&#8217;s effect on various myeloma cell cultures clearly show a strong tumor cell-killing effect. With our clinical experience of OsteoDex&#8217;s effect on disease processes in the skeleton (mCRPC), we have reason to be optimistic about the myeloma study.<\/p>\n<p>At the extraordinary general meeting on 11 May, Andreas Segerros was elected to the board and was appointed chairman of the board on the same day. Andreas Segerros has long and solid experience with executive positions within the international pharmaceutical industry in Europe, the USA and Japan. Andreas Segerros will be a key person in the Company&#8217;s continued development, this in perspective of his previous experience and associated network.<\/p>\n<p>Anders R Holmberg<\/p>\n<p>CEO<\/p>\n<p><a href=\"https:\/\/dextechmedical.com\/wp-content\/uploads\/Dextech-Year-end-report-July-2021-June-2022.pdf\">Dextech &#8211; Year-end report July 2021 &#8211; June 2022<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Summary of the fourth quarter (2022-04-01 \u2013 2022-06-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -2,1 (-1,5) Earnings per share* SEK -0.11 (-0.10) * Before [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-1580","post","type-post","status-publish","format-standard","hentry","category-okategoriserade-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Year-end report July 1, 2021 - June 30, 2022 | DexTech<\/title>\n<meta name=\"description\" content=\"Summary of the fourth quarter (2022-04-01 \u2013 2022-06-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -2,1 (-1,5) Earnings\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2021-30-juni-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Year-end report July 1, 2021 - June 30, 2022 | DexTech\" \/>\n<meta property=\"og:description\" content=\"Summary of the fourth quarter (2022-04-01 \u2013 2022-06-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -2,1 (-1,5) Earnings\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2021-30-juni-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"DexTech\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-30T11:30:43+00:00\" \/>\n<meta name=\"author\" content=\"G\u00f6sta Lundgren\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G\u00f6sta Lundgren\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2021-30-juni-2022\/\",\"url\":\"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2021-30-juni-2022\/\",\"name\":\"Year-end report July 1, 2021 - June 30, 2022 | DexTech\",\"isPartOf\":{\"@id\":\"https:\/\/dextechmedical.com\/#website\"},\"datePublished\":\"2022-08-30T11:30:43+00:00\",\"author\":{\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\"},\"description\":\"Summary of the fourth quarter (2022-04-01 \u2013 2022-06-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -2,1 (-1,5) Earnings\",\"breadcrumb\":{\"@id\":\"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2021-30-juni-2022\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2021-30-juni-2022\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2021-30-juni-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/dextechmedical.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Year-end report July 1, 2021 &#8211; June 30, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dextechmedical.com\/#website\",\"url\":\"https:\/\/dextechmedical.com\/\",\"name\":\"DexTech\",\"description\":\"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dextechmedical.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\",\"name\":\"G\u00f6sta Lundgren\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"caption\":\"G\u00f6sta Lundgren\"},\"sameAs\":[\"https:\/\/dextechmedical.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Year-end report July 1, 2021 - June 30, 2022 | DexTech","description":"Summary of the fourth quarter (2022-04-01 \u2013 2022-06-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -2,1 (-1,5) Earnings","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2021-30-juni-2022\/","og_locale":"en_US","og_type":"article","og_title":"Year-end report July 1, 2021 - June 30, 2022 | DexTech","og_description":"Summary of the fourth quarter (2022-04-01 \u2013 2022-06-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -2,1 (-1,5) Earnings","og_url":"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2021-30-juni-2022\/","og_site_name":"DexTech","article_published_time":"2022-08-30T11:30:43+00:00","author":"G\u00f6sta Lundgren","twitter_misc":{"Written by":"G\u00f6sta Lundgren","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2021-30-juni-2022\/","url":"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2021-30-juni-2022\/","name":"Year-end report July 1, 2021 - June 30, 2022 | DexTech","isPartOf":{"@id":"https:\/\/dextechmedical.com\/#website"},"datePublished":"2022-08-30T11:30:43+00:00","author":{"@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c"},"description":"Summary of the fourth quarter (2022-04-01 \u2013 2022-06-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -2,1 (-1,5) Earnings","breadcrumb":{"@id":"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2021-30-juni-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2021-30-juni-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2021-30-juni-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dextechmedical.com\/en\/"},{"@type":"ListItem","position":2,"name":"Year-end report July 1, 2021 &#8211; June 30, 2022"}]},{"@type":"WebSite","@id":"https:\/\/dextechmedical.com\/#website","url":"https:\/\/dextechmedical.com\/","name":"DexTech","description":"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dextechmedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c","name":"G\u00f6sta Lundgren","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","caption":"G\u00f6sta Lundgren"},"sameAs":["https:\/\/dextechmedical.com"]}]}},"_links":{"self":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/comments?post=1580"}],"version-history":[{"count":1,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1580\/revisions"}],"predecessor-version":[{"id":1583,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1580\/revisions\/1583"}],"wp:attachment":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/media?parent=1580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/categories?post=1580"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/tags?post=1580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}